Sul Numero Cromosomico di Matteuccia Struthiopteris (L.) Todaro

RIASSUNTOIn due esemplari di Matteuccia struthiopteris (L.) Todaro coltivati nell'Orto Botanico dell'Universita di Firenze lo studio della meiosi di molte cellule madri delle spore ha messo in luce la presenza di 39 bivalentti. Gli Autori che precedentemente hanno studiato la specie riportano n=40 oppure n=c.40

Surgical Ventricular Restoration to Reverse Left Ventricular Remodeling

Heart failure is one of the major health care issues in the Western world. An increasing number of patients are affected, leading to a high rate of hospitalization and high costs. Even with administration of the best available medical treatment, mortality remains high. The increase in left ventricular volume after a myocardial infarction is a component of the remodeling process. Surgical Ventricular Restoration (SVR) has been introduced as an optional therapeutic strategy to reduce left ventricular volume and restore heart geometry. So far, it has been established that SVR improves cardiac function, clinical status, and survival in patients with ischemic, dilated cardiomyopathy and heart failure. Since its first description , SVR has been refined in an effort to standardize the procedure and to optimize the results. This review will discuss the rationale behind surgical reversal of LV remodeling, the SVR technique, its impact on cardiac function and survival, and future expectations

Surgical ventricular reconstruction with different myocardial protection strategies. A propensity matched analysis☆

n/

An adjusted EuroSCORE model for high-risk cardiac patients

n/

Cirugía de restauración ventricular para revertir el remodelado del ventrículo izquierdo

La insuficiencia cardíaca (IC) es uno de los problemas de salud de mayor importancia en el mundo occidental en cuanto a número creciente de pacientes afectados, tasa de hospitalización y costes. A pesar de la optimización en el tratamiento médico, la mortalidad permanece elevada. El incremento del volumen ventricular tras un infarto de miocardio (IM) forma parte del proceso de remodelado. la cirugía de restauración ventricular (SVR) se introdujo como una opción terapéutica con el objetivo de reducir los volúmenes ventriculares y restaurar la geometría. Hasta ahora, se ha demostrado que la SVR mejora la función cardíaca, el estadio clínico y la supervivencia en pacientes con miocardiopatía dilatada isquémica e IC. la técnica, desde su descripción inicial, se ha refinado en los últimos 10 años en un esfuerzo para estandarizar el procedimiento y optimizar los resultados. En esta revisión se discuten las razones de revertir quirúrgicamente el remodelado de ventrículo izquierdo (VI) , la técnica, el impacto de la SVR en la función cardíaca y la supervivencia, y una información actualizada sobre los ensayos clínicos actuales y las nuevas guías clínicas.Heart failure is one of the major health care issues in the Western world in terms of increasing number of patients affected, rate of hospitalization, and costs. Despite optimal medical treatment, mortality remains high. The increase in left ventricular volume after a myocardial infarction is a component of the remodeling process. Surgical ventricular restoration (SVR) has been introduced as an optional therapeutic strategy aimed to reduce left ventricular volumes and restore geometry. So far, it has been established that SVR improves cardiac function, clinical status, and survival in patients with ischemic, dilated cardiomyopathy and heart failure. The technique, since its first description, has been refined in the last ten years in an effort to standardize the procedure and to optimize the results. This review will discuss the rationale to surgically reverse lV remodeling, the technique, the impact of SVR on cardiac function and survival, and an up-to-date information regarding the current trials and the new guidelines

Surgical therapy for ischemic heart failure: Single-center experience with surgical anterior ventricular restoration

ObjectivesOur objectives were (1) to report operative and long-term mortality in patients submitted to anterior surgical ventricular restoration, (2) to report changes in clinical and cardiac status induced by surgical ventricular restoration, and (3) to report predictors of death in a large cohort of patients operated on at San Donato Hospital, Milan, Italy.MethodsA total of 1161 consecutive patients (83% men, 62 ± 10 years) had anterior surgical ventricular restoration with or without coronary artery bypass grafting and with or without mitral repair/replacement. A complete echocardiographic study was performed in 488 of 1161 patients operated on between January 1998 and October 2005 (study group). The indication for surgery was heart failure in 60% of patients, angina, and/or a combination of the two.ResultsThirty-day cardiac mortality was 4.7% (55/1161) in the overall group and 4.9% (24/488) in the study group. Determinants of hospital mortality were mitral valve regurgitation and need for a mitral valve repair/replacement. Mitral regurgitation (>2+) associated with a New York Heart Association class greater than II and with diastolic dysfunction (early-to-late diastolic filling pressure >2) further increases mortality risk. Global systolic function improved postoperatively: ejection fraction improved from 33% ± 9% to 40% ± 10% (P < .001); end-diastolic and end-systolic volumes decreased from 211 ± 73 to 142 ± 50 and 145 ± 64 to 88 ± 40 mL, respectively (P < .001) early after surgery. New York Heart Association functional class improved from 2.7 ± 0.9 to 1.6 ± 0.7 (P < .001) late after surgery. Long-term survival in the overall population was 63% at 120 months.ConclusionsSurgical ventricular restoration for ischemic heart failure reduces ventricular volumes, improves cardiac function and functional status, carries an acceptable operative mortality, and results in good long-term survival. Predictors of operative mortality are mitral regurgitation of 2+ or more, New York Heart Association class greater than II, and diastolic dysfunction (early-to-late diastolic filling pressure >2)

Vegetating nodules following erosions on the oral cavity : a quiz

Acta Derm Venereol 95 © 2015 The Authors. doi: 10.2340/00015555-1936 Journal Compilation © 2015 Acta Dermato-Venereologica. ISSN 0001-5555 A 68-year-old Italian man presented with a 7-month history of multiple erosions on the trunk as well as lips and oral cavity. Before admission to our department, he was treated in another institution with systemic corticosteroids (oral prednisone at the initial dose of 1 mg/kg/day, with progressively tapering dosages for 2 months) and other immunosuppressants, such as azathioprine (1.25 mg/kg/ day for 2 months), intravenous immunoglobulins (one cycle consisting of one infusion of 400 mg/kg/day for 5 consecutive days), and rituximab (one cycle consisting of one infusion of 375 mg/m2/every week for 4 weeks), achieving resolution of the cutaneous manifestations but without control of the oral involvement. Upon admission, he had multiple lip and oral erosions (Fig. 1a). In the following days, he developed erythematous-violaceous vegetating nodules that coalesced into ulcerated plaques on the lips and tongue (Fig. 1b). The patient's general condition was compromised; he was asthenic and, due to dysphagia, had lost about 15 kg in the last 3 months. Staging fibroscopy revealed nodules that induced marked stenosis of the larynx and pharynx (Fig. 1c). Within a few days, an emergency tracheotomy was required because of acute dyspnea. Biopsy specimens from a nodule were submitted for histology (Fig. 1d)

Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)

In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis